Objective: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between glatiramer acetate (GA) and interferon-beta (IFNb) after an on-treatment relapse on IFNb or GA using propensity score matched real-world datasets. Methods: Patients included were registered in MSBase or the TYSABRI Observational Program (TOP), had relapsed on IFNb or GA within 12 months prior to switching to another therapy, and had initiated natalizumab or IFNb/GA treatment ≤6 months after discontinuing prior therapy. Covariates were balanced across post switch treatment groups by propensity score matching at treatment initiation. Relapse, persistence, and disability measures were compared between matched treatment arms in the total population (n = 869/group) and in subgroups defined by prior treatment history (IFNb only [n = 578/group], GA only [n = 165/group], or both IFNb and GA [n = 176/group]). Results: Compared to switching between IFNb and GA, switching to natalizumab reduced annualized relapse rate in year one by 65–75%, the risk of first relapse by 53–82% (mean follow-up 1.7–2.2 years) and treatment discontinuation events by 48–65% (all P ≤ 0.001). In the total population, switching to natalizumab reduced the risk of confirmed disability progression by 26% (P = 0.036) and decreased the total disability burden by 1.54 EDSS-years (P < 0.0001) over the first 24 months post switch.

Comparative efficacy of switching to natalizumab in active multiple sclerosis

PELLEGRINI, FABIO;TROIANO, Maria;
2015-01-01

Abstract

Objective: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between glatiramer acetate (GA) and interferon-beta (IFNb) after an on-treatment relapse on IFNb or GA using propensity score matched real-world datasets. Methods: Patients included were registered in MSBase or the TYSABRI Observational Program (TOP), had relapsed on IFNb or GA within 12 months prior to switching to another therapy, and had initiated natalizumab or IFNb/GA treatment ≤6 months after discontinuing prior therapy. Covariates were balanced across post switch treatment groups by propensity score matching at treatment initiation. Relapse, persistence, and disability measures were compared between matched treatment arms in the total population (n = 869/group) and in subgroups defined by prior treatment history (IFNb only [n = 578/group], GA only [n = 165/group], or both IFNb and GA [n = 176/group]). Results: Compared to switching between IFNb and GA, switching to natalizumab reduced annualized relapse rate in year one by 65–75%, the risk of first relapse by 53–82% (mean follow-up 1.7–2.2 years) and treatment discontinuation events by 48–65% (all P ≤ 0.001). In the total population, switching to natalizumab reduced the risk of confirmed disability progression by 26% (P = 0.036) and decreased the total disability burden by 1.54 EDSS-years (P < 0.0001) over the first 24 months post switch.
File in questo prodotto:
File Dimensione Formato  
spelman2015.pdf

accesso aperto

Tipologia: Documento in Versione Editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 778.92 kB
Formato Adobe PDF
778.92 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/170022
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 47
social impact